ID   Ma-Mel-KNUD
AC   CVCL_C505
SY   KNUD; MaMel-KNUD; MaMel_KNUD
DR   cancercelllines; CVCL_C505
DR   Cosmic; 1467781
DR   Cosmic; 2163834
DR   Cosmic; 2686498
DR   ESTDAB; ESTDAB-136
DR   GEO; GSM109094
DR   GEO; GSM437046
DR   IGRhCellID; MaMel_KNUD
DR   Progenetix; CVCL_C505
DR   Wikidata; Q54903873
RX   PubMed=16827748;
RX   PubMed=19340423;
RX   PubMed=20544847;
RX   PubMed=23348503;
RX   PubMed=23851445;
RX   PubMed=26909863;
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=26909863).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1788; CDKN2B; Zygosity=Homozygous (PubMed=26909863).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=16827748; PubMed=23348503; PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Leu247Ter (c.740T>G); ClinVar=VCV000428210; Zygosity=Unspecified (PubMed=23851445).
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
ST   Source(s): ESTDAB=ESTDAB-136
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 8
ST   D3S1358: 14,17
ST   D5S818: 11,12
ST   D7S820: 10,11
ST   FGA: 20,24
ST   TH01: 9.3
ST   TPOX: 8,12
ST   vWA: 17,18
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 19-12-24; Version: 18
//
RX   PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x;
RA   Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R.,
RA   Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D.,
RA   Dummer R.;
RT   "Metastatic potential of melanomas defined by specific gene expression
RT   profiles with no BRAF signature.";
RL   Pigment Cell Res. 19:290-302(2006).
//
RX   PubMed=19340423; DOI=10.1007/s00262-009-0701-z; PMCID=PMC11030131;
RA   Mendez R., Aptsiauri N., Del Campo A., Maleno I., Cabrera T.,
RA   Ruiz-Cabello Osuna F., Garrido F., Garcia-Lora A.;
RT   "HLA and melanoma: multiple alterations in HLA class I and II
RT   expression in human melanoma cell lines from ESTDAB cell bank.";
RL   Cancer Immunol. Immunother. 58:1507-1515(2009).
//
RX   PubMed=20544847; DOI=10.1002/gcc.20785;
RA   Gast A., Scherer D., Chen B.-W., Bloethner S., Melchert S., Sucker A.,
RA   Hemminki K., Schadendorf D., Kumar R.;
RT   "Somatic alterations in the melanoma genome: a high-resolution
RT   array-based comparative genomic hybridization study.";
RL   Genes Chromosomes Cancer 49:733-745(2010).
//
RX   PubMed=23348503; DOI=10.1126/science.1230062;
RA   Horn S., Figl A., Rachakonda P.S., Fischer C., Sucker A., Gast A.,
RA   Kadel S., Moll I., Nagore E., Hemminki K., Schadendorf D., Kumar R.;
RT   "TERT promoter mutations in familial and sporadic melanoma.";
RL   Science 339:959-961(2013).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//
RX   PubMed=26909863; DOI=10.18632/oncotarget.7503; PMCID=PMC4941330;
RA   Xie H.-P., Rachakonda P.S., Heidenreich B., Nagore E., Sucker A.,
RA   Hemminki K., Schadendorf D., Kumar R.;
RT   "Mapping of deletion breakpoints at the CDKN2A locus in melanoma:
RT   detection of MTAP-ANRIL fusion transcripts.";
RL   Oncotarget 7:16490-16504(2016).
//